5-碘-噻吩-2-羧酸 | 60166-85-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-碘-噻吩-2-羧酸
• 英文名称: 5-Iodo-thiophene-2-carboxylic acid
• 英文别名: 5-iodo-2-thiophenecarboxylic acid；5-Iodthiophen-2-carbonsaeure；5-Iodothiophene-2-carboxylic acid
• CAS: 60166-85-0
• 化学式: C₅H₃IO₂S
• 分子量: 254.048
• InChiKey: HQCXDWXNOLVWER-UHFFFAOYSA-N

物化性质

• 熔点：
  133 °C
• 沸点：
  344.0±27.0 °C(Predicted)
• 密度：
  2.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  5-碘-噻吩-2-羧酸 在 溴 作用下， 生成 4,5-二溴噻吩-2-甲酸
  参考文献：
  名称：

  Steinkopf et al., Justus Liebigs Annalen der Chemie, 1937, vol. 527, p. 237,255

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙酰基-5-碘噻吩 在 sodium hydroxide 、 potassium permanganate 作用下， 生成 5-碘-噻吩-2-羧酸
  参考文献：
  名称：

  Rinkes, Recueil des Travaux Chimiques des Pays-Bas, 1934, vol. 53, p. 643,648

  摘要：

  DOI：

文献信息

• Thiophene integrin inhibitors
  申请人：BioChem Pharma Inc.

  公开号：US06274620B1

  公开（公告）日：2001-08-14

  The present invention comprises compounds that are effective inhibitors of integrins, particularly &agr;v&bgr;3 and &agr;v&bgr;5 integrins. Particularly, the compounds are of formula I and pharmaceutically acceptable salts thereof wherein X,Y1 W, R1 to R5, A and B are defined according to the disclosure herein.

  本发明涉及有效抑制整合素的化合物，特别是αvβ3和αvβ5整合素。具体来说，所述化合物具有公式I和其药用盐，其中X、Y1、W、R1至R5、A和B根据本文所披露的定义。
• 3-substituted-2-oxindole derivatives
  申请人：Pfizer Inc.

  公开号：US05047554A1

  公开（公告）日：1991-09-10

  This invention relates to novel 3-substituted-2-oxindole derivatives which are inhibitors of prostaglandin H.sub.2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H.sub.2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H.sub.2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.

  这项发明涉及新型的3-取代-2-噁唑烷酮衍生物，这些衍生物是前列腺素H.sub.2合酶、5-脂氧合酶和白细胞介素-1生物合成的抑制剂。该发明的化合物在慢性炎症性疾病的治疗中可用作前列腺素H.sub.2合酶和白细胞介素-1生物合成的抑制剂，本身也可作为镇痛、抗炎和抗关节炎药物。本发明还涉及包含所述3-取代-2-噁唑烷酮衍生物的药物组合物；抑制前列腺素H.sub.2合酶和白细胞介素-1生物合成的方法；以及使用这些化合物治疗哺乳动物的慢性炎症性疾病。此外，本发明还涉及某些新型羧酸，可用作本发明的3-取代-2-噁唑烷酮衍生物的合成中间体，以及一种制备这些衍生物的方法。
• Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05278153A1

  公开（公告）日：1994-01-11

  Phosphonic acid squalene synthetase inhibitors are provided which are effective in lowering serum cholesterol and have the formula ##STR1## wherein m is 0 to 3, n is 1 to 5, Y.sup.1 and Y.sup.2 are H or halogen, R.sup.2, R.sup.3 and R.sup.4 are H, metal ion, C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.12 alkenyl, or prodrug ester, and R.sup.1 is a substituted or unsubstituted heteroaryl group or a substituted phenyl group.

  提供了磷酸醇鱼肝油合成酶抑制剂，可有效降低血清胆固醇，其化学式为##STR1##其中m为0至3，n为1至5，Y.sup.1和Y.sup.2为H或卤素，R.sup.2、R.sup.3和R.sup.4为H、金属离子、C.sub.1到C.sub.8烷基、C.sub.3到C.sub.12烯基或前药酯，而R.sup.1为取代或未取代的杂环芳基或取代的苯基。
• 2-carboxy-thiophene derivatives
  申请人：Pfizer Inc.

  公开号：US05300655A1

  公开（公告）日：1994-04-05

  This invention relates to novel 3-substituted-2-oxindole derivatives which are inhibitors of prostaglandin H.sub.2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H.sub.2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H.sub.2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.

  本发明涉及新型的3-取代-2-氧化吲哚衍生物，其是前列腺素H.sub.2合酶、5-脂氧合酶和白细胞介素-1生物合成的抑制剂。本发明中的化合物本身作为前列腺素H.sub.2合酶和白细胞介素-1生物合成的抑制剂以及作为治疗慢性炎症性疾病的镇痛、抗炎和抗关节炎药物是有用的。本发明还涉及包含所述3-取代-2-氧化吲哚衍生物的制药组合物；抑制前列腺素H.sub.2合酶和白细胞介素-1生物合成的方法；以及使用该化合物治疗哺乳动物的慢性炎症性疾病。此外，本发明还涉及某些新型羧酸，其作为制备本发明的3-取代-2-氧化吲哚衍生物的中间体，以及制备3-取代-2-氧化吲哚衍生物的过程。
• 3-substituted-2-oxindoles derivatives
  申请人：Pfizer Inc.

  公开号：US06174883B1

  公开（公告）日：2001-01-16

  This invention relates to novel 3-substituted-2-oxindole derivatives of the formula and the phamaceutically-accepted salts thereof which are inhibitors of prostaglandin H2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.

  本发明涉及一种新的3-取代-2-氧化吲哚衍生物及其药物接受的盐，它们是前列腺素H2合酶、5-脂氧合酶和白细胞介素-1生物合成的抑制剂。本发明的化合物本身就是前列腺素H2合酶和白细胞介素-1生物合成的抑制剂，可用于治疗慢性炎症性疾病的镇痛、抗炎和抗关节炎药物。本发明还涉及包括所述3-取代-2-氧化吲哚衍生物的制药组合物；抑制前列腺素H2合酶和白细胞介素-1的生物合成的方法；以及使用该化合物治疗哺乳动物的慢性炎症性疾病。此外，本发明还涉及一些新的羧酸，可用作制备本发明的3-取代-2-氧化吲哚衍生物的中间体，以及制备3-取代-2-氧化吲哚衍生物的方法。

表征谱图